Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks,
Gilead Sciences (NASDAQ:GILD) Hits New 12-Month High on Earnings Beat
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company traded as high as $104.
Gilead Sciences: Strong Q4 Results And Huge Progress In HIV
Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.
Q4 2024 Gilead Sciences Inc Earnings Call
Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.27% to 6,051.97 and Dow Jones Industrial Average falling 0.
Gilead Sciences (GILD) Tops Q4 Earnings and Revenue Estimates
Gilead Sciences (GILD) came out with quarterly earnings of $1.90 per share, beating the Zacks Consensus Estimate of $1.67 per share. This compares to earnings of $1.72 per share a year ago. These figures are adjusted for non-recurring items.
Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects the full year’s revenue to be around $28.4 billion,
Yahoo Finance3d
Gilead Sciences (GILD) Q4 Earnings: What To Expect
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7.
Business Wire16d
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released o ...
3 Top AI-Powered Biotech Stocks to Buy in February
AbbVie ( ABBV 0.64%) is a leader in biopharmaceuticals with a product portfolio spanning multiple therapeutic areas, ...
Ideaya Biosciences enters additional supply pact with Gilead for IDE397
Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...
Reuters1mon
Gilead Sciences, US government settle patent case over HIV prevention drugs
Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according ...
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...